|本期目录/Table of Contents|

[1]杨雪玢,吴晓奇,郭建军,等.天麻素与灵芝三萜组合物对阿尔茨海默病细胞模型GSK-3β通路的作用及机制[J].浙江理工大学学报,2026,55-56(自科四):524-536.
　YANGXuebin,WUXiaoqi,GUOJianjun,et al.Effect and mechanism of Gastrodin and Ganoderma lucidum triterpenoids compositiononGSK-3pathway in Alzheimer’s disease cell model[J].Journal of Zhejiang Sci-Tech University,2026,55-56(自科四):524-536.
点击复制

天麻素与灵芝三萜组合物对阿尔茨海默病细胞模型GSK-3β通路的作用及机制()

浙江理工大学学报[ISSN:1673-3851/CN:33-1338/TS]

卷:
55-56
期数:
2026年自科第四期
页码:
524-536
栏目:
出版日期:
2026-07-10

文章信息/Info

Title:
Effect and mechanism of Gastrodin and Ganoderma lucidum triterpenoids compositiononGSK-3pathway in Alzheimer’s disease cell model
文章编号:
1673-3851(2026) 07-0524-13
作者:
杨雪玢 ; 吴晓奇 ; 郭建军 ; 盛清
1. 浙江理工大学生命科学与医药学院 ,杭州 310018;2. 浙江理工大学绍兴生物医药研究院 ,浙江绍兴 312000
Author(s):
YANGXuebin ; WUXiaoqi ; GUOJianjun ; SHENGQing
1. College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China; 2. Zhejiang Sci-Tech University Shaoxing Academy of Biomedicine, Shaoxing312000, China
关键词:
天麻素 ; 灵芝三 萜 ;  阿尔茨海默病 ; 糖原合成酶激酶-3β; Tau蛋白过度磷酸化
分类号:
R742
文献标志码:
A
摘要:
为探究药食同源活性成分天麻素(Gastrodin, GAS)与灵芝三 萜 (Ganoderma lucidum triterpenoids, GLT)的组合物在阿尔茨海默病(Alzheimer’s disease,AD) 中的作用及机制 ,采用网络药理学方法分析 GAS与 GLT在 AD 中的潜在作用靶点及其相关信号通路 ,通过 CCK-8及氧化应激实验探究 GAS与 GLT对细胞活力及氧化应激状态影响 ,并通过 Westernblotting与 RT-qPCR技术分析糖原合成酶激酶-3β(Glycogen synthasekinase-3β, GSK- 3β) 、p-Tau(Thr181)和 p-Tau(Ser396)的蛋白含量及 mRNA表达水平的变化情况 。结果表明 :40μg/mL GAS与 20 μg/mL GLT按照 1∶1、1∶2、2∶1体积比制备的组合物可逆转 β-淀粉样蛋白 25-35(Aβ25-35)引起的AD细胞模型氧化应激损伤并抑制细胞凋亡 (P<0.05) ; 组合物体积比为 2∶1时能够抑制 GSK-3β蛋白活化 , 缓解 p-Tau(Thr181)和p-Tau(Ser396)的异常磷酸化(P<0.05) ;GAS与 GLT组合物可显著减轻 Aβ引发的氧化应激反应、抑制细胞凋亡 ,并抑制 Tau蛋白的过度磷酸化 。该研究为利用药食同源活性成分发挥协同效开展 AD预防与治疗提供了新思路。

参考文献/References:

[1] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease[J]. The Lancet, 2021, 397(10284):1577‑1590.
[2] Zheng Q Y, Wang X. Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy[J]. Protein & Cell, 2025, 16(2):83‑120.
[3] Baviskar P S, Mahajan H S. Unveiling Alzheimer’s disease (1901-2025): historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies[J]. Ageing Research Reviews, 2026, 114:102990.
[4] Srivastava S, Ahmad R, Khare S K. Alzheimer’s disease and its treatment by different approaches: a review[J]. European Journal of Medicinal Chemistry, 2021, 216:113320.
[5] Ameli Mojarad M, Ameli Mojarad M. The neuroinflammatory role of microglia in Alzheimer’s disease and their associated therapeutic targets[J]. CNS Neuroscience & Therapeutics, 2024, 30(7):e14856.
[6] Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease[J]. Human Molecular Genetics, 2010, 19(R1):R12‑R20.
[7] 宋博雅. 阿尔茨海默病发病机制的研究进展[J]. 西安文理学院学报(自然科学版), 2020, 23(4):77‑79,92.
[8] He Z H, Guo J L, McBride J D, et al. Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation[J]. Nature Medicine, 2018, 24(1):29‑38.
[9] Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer’s disease[J]. Oxidative Medicine and Cellular Longevity, 2013, 2013.
[10] Ionescu-Tucker A, Cotman C W. Emerging roles of oxidative stress in brain aging and Alzheimer’s disease[J]. Neurobiology of Aging, 2021, 107:86‑95.
[11] Matias M, Silvestre S, Falcão A, et al. Gastrodia elata and epilepsy: rationale and therapeutic potential[J]. Phytomedicine, 2016, 23(12):1511‑1526.
[12] Wang Y L, Bai M T, Wang X, et al. Gastrodin: a comprehensive pharmacological review[J]. Naunyn‑Schmiedeberg’s Archives of Pharmacology, 2024, 397(6):3781‑3802.
[13] Wang D, Liu W, Lu M, et al. Neuropharmacological effects of Gastrodia elata Blume and its active ingredients[J]. Frontiers in Neurology, 2025, 16.
[14] Shi R, Zheng C B, Wang H Y, et al. Gastrodin alleviates vascular dementia in a 2-VO vascular dementia rat model by altering amyloid and tau levels[J]. Pharmacology, 2020, 105(7/8):386‑396.
[15] He J Z, Li X, Yang S P, et al. Gastrodin extends the lifespan and protects against neurodegeneration in the Drosophila PINK1 model of Parkinson’s disease[J]. Food & Function, 2021, 12(17):7816‑7824.
[16] Fasina O B, Wang J Y, Mo J X, et al. Gastrodin from gastrodia elata enhances cognitive function and neuroprotection of AD mice via the regulation of gut microbiota composition and inhibition of neuron inflammation[J]. Frontiers in Pharmacology, 2022, 13:814271.
[17] Zhao X M, Zou Y, Xu H, et al. Gastrodin protect primary cultured rat hippocampal neurons against amyloid-beta peptide‑induced neurotoxicity via ERK1/2-Nrf2 pathway[J]. Brain Research, 2012, 1482:13‑21.
[18] Wang W S, Wang Y, Wang F J, et al. Gastrodin regulates the TLR4/TRAF6/NF-κB pathway to reduce neuroinflammation and microglial activation in an AD model[J]. Phytomedicine, 2024, 128:155518.
[19] 罗云, 陈霖, 张雪涟, 等. 灵芝三萜类成分药理活性研究进展[J]. 中国药理学通报, 2021, 37(9):1185‑1188.
[20] Cör D, Knez Ž, Knez Hrnčič M. Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of ganoderma lucidum terpenoids and polysaccharides: a review[J]. Molecules, 2018, 23(3):649.
[21] Galappaththi M C A, Patabendige N M, Premarathne B M, et al. A review of ganoderma triterpenoids and their bioactivities[J]. Biomolecules, 2023, 13(1):24.
[22] Luz D A, Pinheiro A M, Fontes-Júnior E A, et al. Neuroprotective, neurogenic, and anticholinergic evidence of Ganoderma lucidum cognitive effects: crucial knowledge is still lacking[J]. Medicinal Research Reviews, 2023, 43(5):1504‑1536.
[23] Huang C H, Liao Y T, Chen C L, et al. Protective effect of Ganoderma lucidum-fermented crop extracts against hydrogen peroxide-or β-amyloid-induced damage in human neuronal SH-SY5Y cells[J]. BMC Complementary Medicine and Therapies, 2024, 24(1):148.
[24] Chen X J, Deng Z, Zhang L L, et al. Therapeutic potential of the medicinal mushroom Ganoderma lucidum against Alzheimer’s disease[J]. Biomedicine & Pharmacotherapy, 2024, 172:116222.
[25] Sen T, Saha P, Jiang T, et al. Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3β in Alzheimer’s disease[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(8):4418‑4427.
[26] Petit-Paitel A. GSK-3β: a central kinase for neurodegenerative diseases?[J]. medecine, 2010, 26(5):516‑521.
[27] Wu H H, Tang S S, Huang Z Q, et al. Hepatoprotective effects and mechanisms of action of triterpenoids from Lingzhi or reishi medicinal mushroom Ganoderma lucidum (Agaricomycetes) on α-amanitin-induced liver injury in mice[J]. International Journal of Medicinal Mushrooms, 2016, 18(9):841‑850.
[28] Zhao C, Zhang C C, Xing Z, et al. Pharmacological effects of natural Ganoderma and its extracts on neurological diseases: a comprehensive review[J]. International Journal of Biological Macromolecules, 2019, 121:1160‑1178.
[29] Liang C Y, Tian D N, Liu Y Z, et al. Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: ganoderic acids A, C2, D, F, DM, X and Y[J]. European Journal of Medicinal Chemistry, 2019, 174:130‑141.
[30] Yu N H, Huang Y P, Jiang Y, et al. Ganoderma lucidum triterpenoids (GLTs) reduce neuronal apoptosis via inhibition of ROCK signal pathway in APP/PS1 transgenic Alzheimer’s disease mice[J]. Oxidative Medicine and Cellular Longevity, 2020, 2020:9894037.
[31] Zhao J, Wei M, Guo M, et al. GSK3: A potential target and pending issues for treatment of Alzheimer’s disease[J]. CNS Neuroscience & Therapeutics, 2024, 30(7):e14818.
[32] Cai Z Y, Zhao Y, Zhao B. Roles of glycogen synthase kinase 3 in Alzheimer’s disease[J]. Current Alzheimer Research, 2012, 9(7):864‑879.
[33] Jackson G R, Wiedau-Pazos M, Sang T K, et al. Human wild‑type tau interacts with wingless pathway components and produces neurofibrillary pathology in drosophila[J]. Neuron, 2002, 34(4):509‑519.
[34] Zhang Z H, Hartmann H, Minh Do V, et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis[J]. Nature, 1998, 395(6703):698‑702.
[35] Fiorentini A, Rosi M C, Grossi C, et al. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice[J]. PLoS One, 2010, 5(12):e14382.
[36] Ly P T T, Wu Y L, Zou H Y, et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes[J]. Journal of Clinical Investigation, 2013, 123(1):224‑235.
[37] Toledo E M, Inestrosa N C. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer’s disease[J]. Molecular Psychiatry, 2010, 15(3):272‑285.
[38] Zhao L, Zhang H, Li N, et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula[J]. Journal of Ethnopharmacology, 2023, 309:116306.
[39] Bai R R, Guo J N, Ye X Y, et al. Oxidative stress: the core pathogenesis and mechanism of Alzheimer’s disease[J]. Ageing Research Reviews, 2022, 77:101619.
[40] D’Alessandro M C B, Kanaan S, Geller M, et al. Mitochondrial dysfunction in Alzheimer’s disease[J]. Ageing Research Reviews, 2025, 107:102713.
[41] Sun C B, Gao X Y, Sha S, et al. Berberine alleviates Alzheimer’s disease by activating autophagy and inhibiting ferroptosis through the JNK-p38 MAPK signaling pathway[J]. International Immunopharmacology, 2025, 155:114550.
[42] Zhang W D, Ding F, Rong X, et al. Aβ-induced excessive mitochondrial fission drives type H blood vessels injury to aggravate bone loss in APP/PS1 mice with Alzheimer’s disease[J]. Aging Cell, 2025, 24(2):e14374.
[43] Özdemir A Y, Hofbauerová K, Kopecký V, et al. Different amyloid β42 preparations induce different cell death pathways in the model of SH-SY5Y neuroblastoma cells[J]. Cellular & Molecular Biology Letters, 2024, 29(1).
[44] Cheignon C, Tomas M, Bonnefont-Rousselot D, et al. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease[J]. Redox Biology, 2018, 14:450‑464.
[45] Pu K T, Yang S M, Sheng R L, et al. Chuanxiong-Danggui herb pair alleviated cognitive deficits of APP/PS1 mice by promoting mitophagy[J]. Journal of Ethnopharmacology, 2025, 350:119988.
[46] Ye J X, Wu J Y, Ai L, et al. Geniposide effectively safeguards HT22 cells against Aβ-induced damage by activating mitophagy via the PINK1/Parkin signaling pathway[J]. Biochemical Pharmacology, 2024, 226:116296.
[47] Sayas C L, Ávila J. GSK-3 and tau: a key duo in Alzheimer’s disease[J]. Cells, 2021, 10(4):721.

备注/Memo

备注/Memo:
基金项目 : 浙江理工大学绍兴生物医药研究院开放基金(SXAB202007)收稿日期 : 2025-12-18 网络出版日期 : 2026-03-30
作者简介 : 杨雪玢(1999— ) ,女 ,贵阳人 ,硕士研究生 ,主要从事生物医药方面的研究。通信作者: 盛 清,E-mail: csheng@zstu. edu. cn第 4期 杨雪玢等 :天麻素与灵芝三萜组合物对阿尔茨海默病细胞模型 GSK-3β通路的作用及机制 525
更新日期/Last Update: 2026-07-05